BIOMAT Database Logo BIOMAT Database Logo

Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. 2024

Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Departments of Clinical Laboratory.

This study aimed to retrospectively explore the relationship between clinical efficacy and plasma concentration-dose ratio of risperidone (RIS) in 252 patients with schizophrenia taking RIS orally. After the same dose of RIS treatment, the plasma concentration of RIS/9-hydroxyrisperidone (9-OH-RIS), the total plasma concentration of RIS, and the ratio of the steady-state plasma concentration to the daily dose of the total active product (C/D) showed individual difference. The RIS plasma concentration was significantly higher in patients taking high doses than those taking lower doses ( P  = 0.003). There was a statistically significant difference in C/D ratio between males and females ( P  = 0.003). There were significant differences in ratio of C/D and the total plasma concentration of RIS between patients under 60 years and over 60 years ( P  = 0.016; P  = 0.005). Logistic regression analysis showed that the therapeutic effect and adverse reactions of RIS were correlated with the ratio of C/D in patients with schizophrenia ( P  = 0.038; P  < 0.001). It has been suggested that the importance of monitoring of the plasma concentration of RIS in patients with schizophrenia and the ratio of C/D may be used as the reference for RIS personalized treatment.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068882 Paliperidone Palmitate A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA. 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one,9-Hydroxy-risperidone,9-Hydroxyrisperidone,9-OH-risperidone,Invega,Invega Sustenna,Paliperidone,R 76477,R-76477,9 Hydroxy risperidone,9 Hydroxyrisperidone,9 OH risperidone,Palmitate, Paliperidone,R76477,Sustenna, Invega
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018967 Risperidone A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. R-64,766,R-64766,Risperdal Consta,Risperidal,Consta, Risperdal,R 64,766,R 64766,R64,766,R64766

Related Publications

Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
January 2001, Psychopharmacology,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
July 2010, Journal of psychopharmacology (Oxford, England),
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients.
December 2002, Journal of psychopharmacology (Oxford, England),
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium.
November 2005, International clinical psychopharmacology,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia.
January 2021, Neuropsychiatric disease and treatment,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Risperidone: clinical safety and efficacy in schizophrenia.
January 1992, Psychopharmacology bulletin,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between plasma concentration and dose of digoxin in patients with and without renal impairment.
December 1978, Circulation,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice.
May 2005, Pharmacopsychiatry,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China.
April 2024, World journal of psychiatry,
Qiuying Chen, and Jie Min, and Haibo Yin, and Wenying Xia, and Yimin Shen, and Ming Shu
Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.
May 2014, Human psychopharmacology,
Copied contents to your clipboard!